Manitoba C. Difficile Prevention Proposal

PARTNER WITH US

Healthcare Investment Proposal

Revolutionary C. Difficile Prevention Solution

Transforming Healthcare Through Innovative Preventive Medicine

MB Government

Fund this trial as a healthcare cost-saving investment. Our innovative solution offers the potential to significantly reduce healthcare expenditures by preventing costly C. difficile infections before they occur. By investing now, you can save millions in future healthcare costs while improving patient outcomes across the province.

MB Healthcare Leaders

Endorse this trial to protect seniors, reduce AMR burdens and CDI workloads. Our preventive approach will safeguard vulnerable populations, particularly seniors, while alleviating pressure on healthcare staff. By reducing antimicrobial resistance challenges and C. difficile infection rates, we can improve healthcare efficiency and patient safety.

MB Investors

Fund this trial for the World's only preventive treatment against C. Difficile Infection. With potential annual revenues in excess of $5B and a substantial 45% tax credit, this represents an unparalleled opportunity. Invest in groundbreaking medical innovation with exceptional financial returns and meaningful societal impact.

Manitoba CDI Prevention Proposal
A Made-in-Manitoba and World's First and Only Solution to Prevent Deadly C. Difficile Infection, Save Healthcare Costs & Support Local Agriculture

CDI infections cost Manitoba healthcare millions, endanger seniors, and fuel antibiotic resistance—while infecting the Indigenous population at twice the rate. Manitoba can lead the world in stopping CDI, with a safe, natural solution developed locally by Manitoba scientists, produced by our farmers, and proven 94% effective at curing active infections.

The Problem: CDI is Costly & Deadly in MB Hospitals

  • Seniors (65+) entering MB hospitals face high CDI risk, with ~10% mortality.
  • Treatment costs per CDI case exceed $20,000 (antibiotics, extended stays, isolation).
  • AMR (antimicrobial resistance) is worsened by repeated antibiotic use for CDI.

Our Solution: IgY Antibody Prevention

94%
Effective in curing active CDI
0
Drugs or chemicals
36
Day prevention protocol
  • Proven Science: Same antibodies used in our Phase 2 therapeutic trial cured 94% of CDI patients.
  • Safe & Simple: Pasteurized, spray-dried egg powder (oral daily dose). Zero drugs or chemicals.
  • Prevention Protocol: 36-day course for at-risk seniors upon hospital entry.

Why Manitoba? A Win-Win Solution

Save Healthcare Dollars

Approximately 2,500 susceptible seniors (65+) enter Manitoba hospitals every month.
$1M/month prevention treatment cost vs $1.5M/month in avoided costs to treat infected patients (based on 75 preventable cases per month). This amounts to $500,000 savings to MB healthcare and taxpayers monthly.

Net savings projected within months, freeing up beds and resources.

Boost Local Economy

90,000 MB eggs/month sourced from Manitoba farmers → direct agricultural support. This number raises to 22 million eggs per year to supply Canadian hospitals and the requirement of 7 new egg layer barns.

Jobs sustained and increased at our MB-based biotech facility.

Lead Medical Innovation

Position MB as a pioneer in preventive healthcare and AMR reduction.

Successful trial = global export potential to Canada and government-payer systems (UK, EU, Australia).

Prevent a Terrible Infection and Possible Death

C. Difficile infects and kills 500,000 and 30,000 people respectively in North America every year. The same mortality as Prostate Cancer.

The Proposal: A Low-Cost Short-Term Proof of Concept Trial

300
Seniors/month
3
Month trial
$5M
Total investment
  • 3-month pilot: Administer to 300 seniors/month entering MB hospital.
  • Cost to MB:$5M (fully covers doses, production, monitoring).
  • Success Metric: CDI case reduction vs. historical data—no placebo group needed.
  • Safety: Egg powder is food-grade with decades of safe use globally.

Why This is Low-Risk & High-Value

Efficacy Signal: 94% cure rate in active CDI patients strongly supports preventive potential.
Safety Assured: No novel chemicals—only egg antibodies (GRAS: Generally Recognized As Safe).
Exit Strategy: If unsuccessful, total cost is $5M. If successful, MB recoups investment in 10 months and then is ahead by $6M every year. Added bonus is increased agricultural and commercial benefits.

"Manitoba has a unique opportunity: leverage homegrown science and local resources to prevent a deadly infection, save millions in avoidable costs, and showcase our province as a leader in pragmatic healthcare innovation. Let’s turn our eggs into life-saving shields—and our farms into frontline healthcare partners."

- A Made-in-Manitoba Solution

Summary

1 Anchoring Savings

$1M/month cost with $1.5M+/month savings.

2 Local Pride

"Made in MB" eggs, jobs, and science.

3 Urgency

CDI’s 10% mortality in seniors.

4 Risk Mitigation

Patient-safe food product with nutritional benefits.

5 Bigger Vision

MB as a global proof-of-concept leader.

Healthcare Investment Highlights

MB Government

Fund this trial as a healthcare cost-saving investment

MB Healthcare Leaders

Endorse this trial to protect seniors, reduce AMR burdens and CDI workloads

MB Investors

Fund this trial for the World's only preventive treatment against C. Difficile Infection
Potential annual revenues in excess of $5B
45% tax credit
Scroll to Top